The company was founded by Paul Rennert and Roy Lobb, who bring extensive scientific and leadership experience in immunology, oncology and drug development to this new enterprise. Aleta Bio has created a unique portfolio of multi-antigen targeting solutions for cell therapy, designed to address the critical issues of CAR-T persistence, tumor antigen loss leading to patient relapse, and tumor antigen heterogeneity.
Aleta Biotherapeutics was awarded two patents by the USPTO on 11 September 2018. The patents, US10,072,094 and US10,066,023, cover specific aspects of the use of Aleta’s IMPACT™ technology in the field of gene therapy.
Aleta Biotherapeutics will present a poster entitled “Hijacked CAR19 T cells have potent activity against solid tumors” at the upcoming Society for Immunotherapy of Cancer Annual Meeting in Washington DC, 9-11 November 2018. The presentation, poster #P267, will provide an update of Aleta’s IMPACT™ CAR-T cell technology.